For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
11
views
33
references
 Top references
cited by
3
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
1 collections
    0
    shares
      97
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Best Achievements in Clinical Thyroidology in 2020

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This review highlights the most interesting research in thyroidology conducted in 2020. The publications of interest discussed below dealt with the following topics: thyroid dysfunction, risk of thyroid cancer, molecular diagnostics and new therapeutics for thyroid cancer, and thyroid disease in the coronavirus disease 2019 pandemic era.

          Related collections

          Most cited references33

          • Record: found
          • Abstract: found
          • Article: not found

          Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

          Robert Doebele, Alexander Drilon, Luis Paz-Ares … (2019)
          Entrectinib is a potent inhibitor of tropomyosin receptor kinase (TRK) A, B, and C, which has been shown to have anti-tumour activity against NTRK gene fusion-positive solid tumours, including CNS activity due to its ability to penetrate the blood-brain barrier. We present an integrated efficacy and safety analysis of patients with metastatic or locally advanced solid tumours harbouring oncogenic NTRK1, NTRK2, and NTRK3 gene fusions treated in three ongoing, early-phase trials.
          Article 0 comments Cited 463 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

            David S. Hong, Steven DuBois, Shivaani Kummar … (2020)
            Background The selective TRK inhibitor larotrectinib was approved for paediatric and adult patients with advanced TRK fusion-positive solid tumours based on a primary analysis set of 55 patients. The aim of our analysis was to explore the efficacy and long-term safety of larotrectinib in a larger population of patients with TRK fusion-positive solid tumours. Methods Patients were enrolled and treated in a phase 1 adult, a phase 1/2 paediatric, or a phase 2 adolescent and adult trial. Some eligibility criteria differed between these studies. For this pooled analysis, eligible patients were aged 1 month or older, with a locally advanced or metastatic non-CNS primary, TRK fusion-positive solid tumour, who had received standard therapy previously if available. This analysis set includes the 55 patients on which approval of larotrectinib was based. Larotrectinib was administered orally (capsule or liquid formulation), on a continuous 28-day schedule, to adults mostly at a dose of 100 mg twice daily, and to paediatric patients mostly at a dose of 100 mg/m 2 (maximum of 100 mg) twice daily. The primary endpoint was objective response as assessed by local investigators in an intention-to-treat analysis. Contributing trials are registered with ClinicalTrials.gov , NCT02122913 (active not recruiting), NCT02637687 (recruiting), and NCT02576431 (recruiting). Findings Between May 1, 2014, and Feb 19, 2019, 159 patients with TRK fusion-positive cancer were enrolled and treated with larotrectinib. Ages ranged from less than 1 month to 84 years. The proportion of patients with an objective response according to investigator assessment was 121 (79%, 95% CI 72–85) of 153 evaluable patients, with 24 (16%) having complete responses. In a safety population of 260 patients treated regardless of TRK fusion status, the most common grade 3 or 4 larotrectinib-related adverse events were increased alanine aminotransferase (eight [3%] of 260 patients), anaemia (six, 2%), and decreased neutrophil count (five [2%]). The most common larotrectinib-related serious adverse events were increased alanine aminotransferase (two [<1%] of 260 patients), increased aspartate aminotransferase (two [<1%]), and nausea (two [<1%]). No treatment-related deaths occurred. Interpretation These data confirm that TRK fusions define a unique molecular subgroup of advanced solid tumours for which larotrectinib is highly active. Safety data indicate that long-term administration of larotrectinib is feasible. Funding Bayer and Loxo Oncology.
            Article 0 comments Cited 308 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Efficacy of Selpercatinib in RET-Altered Thyroid Cancers

              Lori J Wirth, Eric Sherman, Bruce Robinson … (2020)
              RET mutations occur in 70% of medullary thyroid cancers, and RET fusions occur rarely in other thyroid cancers. In patients with RET-altered thyroid cancers, the efficacy and safety of selective RET inhibition are unknown.
              Article 0 comments Cited 224 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (nlm-ta): Endocrinol Metab (Seoul)
                Journal ID (iso-abbrev): Endocrinol Metab (Seoul)
                Title: Endocrinology and Metabolism
                Publisher: Korean Endocrine Society
                ISSN (Print): 2093-596X
                ISSN (Electronic): 2093-5978
                Publication date (Print): February 2021
                Publication date (Electronic): 24 February 2021
                Volume: 36
                Issue: 1
                Pages: 30-35
                Affiliations
                [1 ]Center for Thyroid Cancer, National Cancer Center, Goyang, Korea
                [2 ]Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, Korea
                [3 ]Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
                [4 ]Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea
                Author notes
                Corresponding author: Young Joo Park, Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea, Tel: +82-2-2072-4183, Fax: +82-2-762-2199, E-mail: yjparkmd@ 123456snu.ac.kr
                Author information
                https://orcid.org/0000-0003-0098-0873
                https://orcid.org/0000-0002-3671-6364
                Article
                Publisher ID: enm-2021-103
                DOI: 10.3803/EnM.2021.103
                PMC ID: 7937845
                PubMed ID: 33677923
                SO-VID: 66ae090f-1478-4276-9d2f-9bcfec805fc6
                Copyright © Copyright © 2021 Korean Endocrine Society
                License:

                This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                Date received : 19 January 2021
                Date revision received : 25 January 2021
                Date accepted : 28 January 2021
                Categories
                Subject: Review Article

                Keywords: thyroid diseases,thyroid neoplasms,thyroid hormone,therapeutics,covid-19,molecular diagnostic techniques
                Data availability:
                Keywords: thyroid diseases, thyroid neoplasms, thyroid hormone, therapeutics, covid-19, molecular diagnostic techniques

                Comments

                Comment on this article

                scite_

                Similar content97

                See all similar

                Cited by3

                See all cited by

                Most referenced authors787

                See all reference authors